Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Direct intralymphatic injection of radiolabeled sup 111 In-T101 in patients with cutaneous T-cell lymphoma

Journal Article · · Cancer Research; (USA)
OSTI ID:5985172

Direct intralymphatic administration of radiolabeled monoclonal antibody in targeting antigen-bearing lymphoma cells in regional lymph nodes of patients with cutaneous T-cell lymphoma was evaluated. Seven consecutive patients undergoing staging lymphangiography received intralymphatic infusions of {sup 111}In-T101 to evaluate lymph node involvement. This procedure was accomplished without significant complication. The {sup 111}In-T101 rapidly distributed throughout the regional lymphatic compartment and passed into the systemic circulation. Tumor-bearing sites in the inguinal-femoral lymph nodes retained from 0.42 to 4.8% of the injected dose of radiolabeled antibody. Three patients were upstaged to Stage IVA based on tumor involvement found after radiolymphoscintigraphy-directed biopsy of groin lymph nodes, selected because of intense radioactivity by gamma camera imaging. Compared with previously reported s.c. antibody administration, there was a marked reduction in the radioactive exposure of normal tissues at the injection sites in the lower extremities. Direct intralymphatic delivery of {sup 111}In-T101 appears to be a feasible, efficient method for delivering therapeutic doses of radiolabeled antibody.

OSTI ID:
5985172
Journal Information:
Cancer Research; (USA), Journal Name: Cancer Research; (USA) Vol. 51:2; ISSN CNREA; ISSN 0008-5472
Country of Publication:
United States
Language:
English